Phase 2 N=92 Radiation Therapy in Treating Young Patients With Gliomas
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=55 Study of Breast Cancer Prevention by Letrozole in High Risk Women
Breast Cancer
Primary: Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months — -1.5; -1.1 percentage of cells stained positive — p=0.92
Phase 2 N=23 Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
Anemia, Aplastic · Anemia, Hypoplastic
Primary: Number of Participants With Complete Response at 3 Months. — 0 Participants
Phase 2 N=454 Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults
Norovirus Prevention
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection — 7.8; 64.1; 72.7; 7.8 percentage of participants
Phase 2 N=140 Topiramate for the Treatment of Methamphetamine Dependence - 1
Methamphetamine
Primary: Abstinence (Weeks 6 - 12) — 49; 49; 43; 48 Participants
Phase 2 N=16 Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
Phase 2 N=82 CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma
Primary: Number of Patients Removed From Study Treatment Due to Toxicities — 31 participants
Phase 2 N=17 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: PSA Response as Defined by the Recommendations of the Prostate-Specific Antigen Working Group — 0 participants
Phase 2 N=36 Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
Recurrent Melanoma · Stage IA Melanoma · Stage IB Melanoma
Primary: T Cell Immunity to gp100 Peptide and to E7 12-20 Papilloma Virus Peptide — 0.02; 0.01; 0.97; 0.98 % of CD8+ T cells — p=<.001
Phase 2 N=19 Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
Adult Brain Tumor
Primary: Number of Participants With Objective Response — 3; 1; 5; 9 Participants
Phase 2 N=247 To Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste
Oral Hygiene
Primary: Number of Gingival Bleeding Sites at 24 Weeks — 45.13; 45.84; 18.67; 36.39 number of gingival bleeding sites — p=<0.0001
Phase 2 N=188 Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Diabetes Type 2
Primary: Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements. — 13.70; -3.67; 6.64; 1.66 mg/dL — p=0.0117
Phase 2 N=165 Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
Tension-Type Headache
Primary: Number of Subjects Pain Free — 21; 20; 21; 19 Participants
Phase 2 N=290 A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 — 32.6; 37.5; 63.3; 47.9 percentage…
Phase 2 N=46 Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Carcinoma of Unknown Primary Origin
Primary: Percentage of Participants With Confirmed Tumor Responses — 36 percentage of participants